KatieB Posted July 13, 2021 Share Posted July 13, 2021 Trial ID: NCT02609776 Condition: Non-Small Cell Lung Cancer Intervention: Parallel Assignment Study Type: Interventional Study Phase: I Study Sponsor: Janssen Research & Development, LLC Trial Start Date: May 24, 2016 Trial End Date: November 1, 2023 Participant Goal: 460 Age Group: 18+ years of age Gender: All Contact: JNJ.CT@sylogent.com Study Summary: The CHRYSALIS Study is for adults with previously treated advanced non-small-cell lung cancer (NSCLC). The study is broken down into different parts and is specifically recruiting patients with NSCLC that have a documented primary MET Exon 14 skipping mutation. An investigational medication will be given to eligible participants to assess its the safety, tolerability, and anti-tumor activity. You may be able to take part in the study if you: · Are 18 years or older · Have been diagnosed with metastatic or unresectable NSCLC with a documented primary MET Exon 14 skipping mutation · Must have received prior treatment or declined currently available treatment. There are no limits on lines of prior treatment nor on the type of prior treatment. Patients are eligible post- chemo and post-MET TKI(s). Trial Eligibility Criteria: https://clinicaltrials.gov/ct2/show/NCT02609776?term=61186372EDI1001&draw=2&rank=1 Locations: https://clinicaltrials.gov/ct2/show/NCT02609776?term=61186372EDI1001&draw=2&rank=1 Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.